Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022
Eiger BioPharmaceuticals (Nasdaq: EIGR) will host a conference call on December 8, 2022, at 8:30 AM ET to discuss the Phase 3 D-LIVR study results of their lonafarnib-based treatments for hepatitis delta virus (HDV).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eiger BioPharmaceuticals (Nasdaq: EIGR) will host a conference call on December 8, 2022, at 8:30 AM ET to discuss the Phase 3 D-LIVR study results of their lonafarnib-based treatments for hepatitis delta virus (HDV). This study is significant as Eiger focuses on developing innovative therapies for HDV and other rare diseases. The company’s HDV platform features two first-in-class therapies currently in Phase 3 trials, both of which have received FDA Breakthrough Therapy designation. Investors can access the live call and its replay via Eiger's website.
Positive
- Eiger's HDV platform includes two first-in-class therapies in Phase 3 trials.
- Both therapies have received FDA Breakthrough Therapy designation.
- Significant focus on developing innovative treatments for HDV.
Negative
- None.
Details
News Market Reaction – EIGR
The recorded move for EIGR in the trading session of this news was -69.53%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live Conference Call and Webcast at 8:30 AM ET
PALO ALTO, Calif., Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, December 8, 2022, at 8:30 AM Eastern Time, to discuss the results of the Phase 3 D-LIVR study of lonafarnib-based treatments for HDV.
The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com. To participate in the live call by phone, dial (866) 374-5140 (U.S.) or (404) 400-0571 (International) and enter PIN 79797687#. The webcast will be archived and available for replay for at least 90 days after the event.
About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Contacts
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-host-conference-call-to-discuss-phase-3-d-livr-study-results-of-lonafarnib-based-treatments-in-hepatitis-delta-virus-hdv-on-thursday-december-8-2022-301697555.html
SOURCE Eiger BioPharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.